Chunyan Lei, Keyang Chen, Yu Gu, Yongyu Li, Lu Wang, Xiaoyan Zhu, Qionghua Deng
BACKGROUND: We previously reported that the HMGB1/TLR4 axis promoted inflammation during the acute phase of intracerebral hemorrhage. Given that this phase is known to involve neuronal pyroptosis and neuroinflammation, here we explore whether HMGB1/TLR signaling activate inflammasome and pyroptosis after intracerebral hemorrhage. METHODS: Autologous blood was injected into Sprague-Dawley rats to induce intracerebral hemorrhage. Neurological deficits were assessed using a modified neurological severity score...
July 8, 2024: Journal of Neuroimmunology
Yen T M Nguyen, Lydia Sibley, Piotr Przanowski, Xiao-Yu Zhao, Michael Kovacs, Shengyuan Wang, Marieke K Jones, Maureen Cowan, Wenjie Liu, Andrea R Merchak, Alban Gaultier, Kevin Janes, Chongzhi Zang, Tajie Harris, Sarah E Ewald, Hui Zong
Few T cells infiltrate into primary brain tumors, fundamentally hampering the effectiveness of immunotherapy. We hypothesized that Toxoplasma gondii, a microorganism that naturally elicits a Th1 response in the brain, can promote T cell infiltration into brain tumors despite their immune suppressive microenvironment. Using a mouse genetic model for medulloblastoma, we found that T. gondii infection induced the infiltration of activatable T cells into the tumor mass and led to myeloid cell reprogramming toward a T cell-supportive state, without causing severe health issues in mice...
July 8, 2024: Journal of Neuroimmunology
Hengdao Chen, Jinrong Xiao, Bin Huang, Jun Que, Minsheng Liu
Sleep insufficiency is a significant health problem worldwide, and adolescent sleep restriction (SR) could induce multiple neurodevelopmental disorders in the central nervous system (CNS). Microglial-mediated neuroinflammation plays a vital role in multiple neurological diseases, and recent research showed the regulation effect of immunoproteasome on microglia functions. Geraniol (GER), an important ingredient in many essential oils, possesses diverse pharmacological properties like anti-inflammatory and antioxidant...
June 29, 2024: Journal of Neuroimmunology
Mathias Heikenwalder, Christian Federau, Lotta von Boehmer, Petra Schwarz, Mareike Wagner, Nicolas Zeller, Johannes Haybaeck, Marco Prinz, Burkhard Becher, Adriano Aguzzi
No abstract text is available yet for this article.
June 28, 2024: Journal of Neuroimmunology
Stephen Krieger, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Olivia Kaczmarek, Jared Srinivasan, Nuno Barros, Diana Sima, Annemie Ribbens, Wim Van Hecke, James B Lewin, Jason P Mendoza, Mark Gudesblatt
OBJECTIVE: Evaluate the real-world effect of dimethyl fumarate (DMF) on subclinical biomarkers in patients with relapsing-remitting multiple sclerosis (RRMS) and compare with results from clinical trials. METHODS: Magnetic resonance imaging (MRI) data from 102 RRMS patients were retrospectively collected and processed using icobrain to assess brain atrophy and to assist semi-manual lesion count. RESULTS: Mean (±SD) annualized percent brain volume change in the first 3 years after DMF-initiation were: -0...
June 21, 2024: Journal of Neuroimmunology
Rongrong Zeng, Lu He, Zhuo Kuang, Yiemin Jian, Meijuan Qiu, Yuting Liu, Mengdie Hu, Yizhi Ye, Liwen Wu
The classification of autoimmune encephalitis (AE) is based on the presence of different types of antibodies. Currently, the clinical manifestations and treatment regimens of patients with all types of AE exhibit similarities. However, the presence of immunological distinctions among different types of AE remains uncertain. In this study, we prospectively collected clinical data, as well as blood and cerebrospinal fluid (CSF) samples from patients diagnosed with MOG antibody-associated disease (MOGAD) or GFAP astrocytopathy (GFAP-A), in order to assess changes in inflammatory biomarkers such as immunoglobulin oligoclonal bands, cytokines in serum and CSF, as well as peripheral blood lymphocyte subtypes within different subsets...
June 20, 2024: Journal of Neuroimmunology
Yoav Piura, Noa Bregman, Gitit Kavé, Arnon Karni, Hadar Kolb, Ifat Vigiser, Gregory S Day, Sebastian Lopez-Chiriboga, Tamara Shiner, Keren Regev
Susac syndrome (SuS) presents with encephalopathy, visual disturbances, and hearing loss from immune-mediated microvascular occlusion. While acute SuS is well-described, long-term cognitive outcomes with current treatments are underknown. We assessed ten SuS patients treated in accordance with evidence-based guidelines using immunotherapies targeting humoral and cell-mediated pathways. Patients were followed for a median 3.6 years. Initially, cognition inversely correlated with corpus callosum lesions on MRI...
June 20, 2024: Journal of Neuroimmunology
Ashish O Gupta, Justin W Furcich, David R Nascene, Stephan Kemp, Carina J King, Erin E Nolan, Willa Durose, Bradley S Miller, Paul J Orchard, Troy C Lund
The earliest clinical manifestation of cerebral adrenoleukodystrophy (CALD) is adrenal insufficiency (AI) characterized by elevations in ACTH and loss of cortisol. We showed high (though physiologically achievable) levels of ACTH increases endothelial permeability, increases anisotropy, and increases VEGF secretion. An ACBD1 knockout endothelial cell line had increased sensitivity to ACTH and VEGF. Inhibition of VEGF via application of anti-VEGF (bevacizumab) improved permeability. Six boys with advanced CALD were treated with bevacizumab combined with dexamethasone and ruxolitinib as immune suppressants...
June 13, 2024: Journal of Neuroimmunology
Elijah Lackey, Jeffrey Shen, Aditya Sharma, Christopher Eckstein
Neurosarcoidosis, a rare granulomatous disease, causes inflammation and damage to the central nervous system (CNS). A major diagnostic challenge in neurosarcoidosis is the absence of well-defined biomarkers. The need for biopsy to make the diagnosis can lead to delays and misdiagnosis if histopathology is inaccessible or indeterminate, highlighting the need for more accessible diagnostic indicators. The current gold standard for a "definite" neurosarcoidosis diagnosis requires biopsy of CNS tissue revealing non-caseating granulomas...
June 11, 2024: Journal of Neuroimmunology
Henry Villenheimo, Virpi Glumoff, Sami Räsänen, Airi Jartti, Harri Rusanen, Pirjo Åström, Outi Kuismin, Timo Hautala
BACKGROUND: X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect (XMEN) disease is caused by MAGT1 loss-of-function (LOF) mutations. The disease commonly presents with respiratory symptoms. Although the central nervous system can be affected, the spectrum of neuropsychiatric symptoms is not completely understood. CASES: We describe a XMEN disease family presenting with atypical neuropsychiatric symptoms. The index, a previously healthy male, developed schizophrenia...
June 5, 2024: Journal of Neuroimmunology
Darla Wheeler, Mariam Bezih, Nicholas Lannen
No abstract text is available yet for this article.
June 4, 2024: Journal of Neuroimmunology
Heather Y F Yong, Nicholas J Batty, Isabelle Tottenham, Marcus Koch, Carlos R Camara-Lemarroy
No abstract text is available yet for this article.
June 3, 2024: Journal of Neuroimmunology
Mihyun Hwang, Cornelia C Bergmann
Virus infections and autoimmune responses are implicated as primary triggers of demyelinating diseases. Specifically, the association of Epstein-Barr virus (EBV) infection with development of multiple sclerosis (MS) has re-ignited an interest in virus induced autoimmune responses to CNS antigens. Nevertheless, demyelination may also be caused by immune mediated bystander pathology in an attempt to control direct infection in the CNS. Tissue damage as a result of anti-viral responses or low level viral persistence may lead to immune activation manifesting in demyelinating lesions, axonal damage and clinical symptoms...
June 1, 2024: Journal of Neuroimmunology
Antoine Pegat, Jean-Baptiste Chanson, Pierre Lozeron, Bastien Joubert, Alexandre Bani-Sadr, Isabelle Quadrio, Léo Vidoni, Philippe Latour
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare immune-mediated neuropathy for which there is no clearly identified risk factor. The present study identified rare variants in the FBXO38 gene in three familial cases of CIDP with response to corticosteroids in three generations with incomplete penetrance, and in an unrelated fourth case with diffuse nerve hypertrophy. FBXO38 may be involved in the regulation of the immunity mediated by CD8 T cells, which have an important role in CIDP pathophysiology, through PD1 degradation...
May 28, 2024: Journal of Neuroimmunology
Nassima Behairi, Arezki Samer, Lynda Sahraoui, Djehane Houria Mataam, Ryad Trari, Billel Flissi, Houda Belguendouz, Zine-Charaf Amir, Chafia Touil-Boukoffa
We aimed to investigate ampicillin (AMP) mechanisms in microbiota-gut-brain axis. We evaluated its effect on two gut and brain regions and behavioral performances. We administred AMP (1 g/l) to BALB/c mice for 21 days. Then, we analyzed body weigth change, stool consistency scoring, gut length, intestinal microbiota composition, nitric oxide synthase 2 (NOS2) expression and tissue integrity. We subsequently evaluated NOS2, GFAP, CD68 and NFL cerebral expression and spatial memory.Interestingly, our data showed gut microbiota disruption, NOS2 upregulation and tissue damage, associated to cerebral NOS2, GFAP, CD68 and NFL over-expression and behavioral alteration...
May 20, 2024: Journal of Neuroimmunology
Meghavi Kathpalia, Pinki Mishra, Afsha Majid, Mohd Ashif Khan, Anurag Sharma, Dinesh Bhurani, Nidhi
BACKGROUND AND PURPOSE: Immune dysfunction is one of the risk factors which plays an important role in the development of non-Hodgkin lymphoma (NHL), and inflammation may be involved in its etiology. Minimal data is available on the effect of cytokine levels on neurobehavioral function in lymphoma before the initiation of chemotherapy. Therefore, we aimed to explore the risk of NHL by assessment of cytokine and adipokine levels and their correlation with neurobehavioral changes. METHODS: This case-control study enrolled 62 subjects (age-sex matched: 31 cases and 31 controls)...
May 19, 2024: Journal of Neuroimmunology
S Sriram, Kwang Woon Kim, Åsa Ljunggren-Rose
SUMO (small ubiquitin like modifier) conjugated proteins have emerged as an important post translational modifier of cellular function. SUMOylation modulates several cellular processes involved in transcriptional regulation of genes, protein-protein interactions and DNA damage and repair. Since abnormalities in SUMOylation has been observed in neoplastic and neurodegenerative disorders, the SUMO pathway has become an attractive site for targeting of new therapies to regulate SUMOylation and reduce disease burden...
May 18, 2024: Journal of Neuroimmunology
Angelo Fonseca, Ernestina Santos, Ricardo Taipa
BACKGROUND: Baló's concentric sclerosis (BCS) is a rare variant of multiple sclerosis characterized by unique pathological features of alternating demyelination and preserved myelin. OBJECTIVES: To describe two cases of BCS, radiological and pathological findings and its clinical course. RESULTS: We report two distinct cases of BCS that presented with unique MRI findings suggestive of BCS, but with different clinical courses and responses to treatment...
May 17, 2024: Journal of Neuroimmunology
Morten Zachariassen, Martin Munthe Thomsen, Thore Hillig, Pelle Trier-Petersen, Andreas Vestergaard Jensen, Lennart Jan Friis-Hansen, Christian Thomas Brandt
BACKGROUND: The extracellular matrix protein tenascin-C has been discovered to be an important regulator of the response to tissue injury and repair in cerebrovascular diseases. This study investigated if tenascin-C is released in response to infections in the central nervous system (CNS). METHODS: Tenascin-C concentration in the cerebrospinal fluid (CSF) was measured in patients, (>18 years) with and without CNS infections, admitted to a department of infectious diseases in Denmark...
May 15, 2024: Journal of Neuroimmunology
Melissa A Wright, Mar Guasp, Christian Lachner, Gregory S Day, Grace Gombolay, Maarten J Titulaer, Stacey L Clardy
Neuropsychiatric symptoms in N-methyl-d-aspartate receptor encephalitis (NMDARE) have led some to pursue empiric trials of electroconvulsive therapy (ECT). A scoping review identified 39 patients diagnosed with NMDARE undergoing ECT. Separately, a retrospective cohort was reviewed to characterize 21 patients. Clinical improvement was attributed to ECT in 49% of patients in the scoping review and 19% of patients in the retrospective cohort; timing of immunotherapies was a confounding factor. Worsening of clinical course following ECT was reported in 28% of patients in the scoping review and 38% of patient in the retrospective review...
May 14, 2024: Journal of Neuroimmunology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.